new semaglutide regulations The FDA's Latest on for Weight Loss FDA moves to restrict compounded

These effects likely reflect the drugs influence on reward processing and impulse regulation , not a general suppression of emotion

N Engl J Med 376(23):23002302

Christian Hendershot, director of clinical research at the USC Institute for Addiction Science, who wasnt involved in the new research but has run trials of GLP-1s in addiction

Semaglutide medications are meant for patients with obesity struggling to control hunger and food cravings

In recent years, some patients are choosing long-term low-dose treatment, or microdosing, to help maintain their results. He notes that weight regain after GLP-1 medications is usually gradual compared to earlier classes of weight loss medication where the rebound could be dramatic

Selman Akinci, a former M&A attorney, has launched his new venture named Doctor Adam, which uses the telemedicine approach to enhance healthcare by eliminating intermediaries